These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35463750)

  • 21. Biomarker discovery in cardiac allograft vasculopathy using targeted aptamer proteomics.
    Almufleh A; Zhang L; Mielniczuk LM; Stadnick E; Davies RA; Du Q; Rayner K; Liu PP; Chih S
    Clin Transplant; 2020 Jan; 34(1):e13765. PubMed ID: 31815308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using Both Plasma and Urine Donor-Derived Cell-Free DNA to Identify Various Renal Allograft Injuries.
    Chen XT; Qiu J; Wu ZX; Zhang H; Chen T; Yang SC; Zhao GD; He Y; Shen X; Luo JQ; Huang Y; Wang CX; Chen LZ; Wu CL; Huang G
    Clin Chem; 2022 Jun; 68(6):814-825. PubMed ID: 35587713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiation of noninvasive surveillance for allograft rejection in heart transplant patients > 1 year after transplant.
    Kewcharoen J; Kim J; Cummings MB; Leitner KB; Suzuki EMB; Banerjee D; Lum CJ
    Clin Transplant; 2022 Mar; 36(3):e14548. PubMed ID: 34843112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor-derived cell-free DNA (dd-cfDNA) for detection of allograft rejection in pediatric kidney transplants.
    Puliyanda DP; Swinford R; Pizzo H; Garrison J; De Golovine AM; Jordan SC
    Pediatr Transplant; 2021 Mar; 25(2):e13850. PubMed ID: 33217125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between dd-cfDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort.
    Sawinski DL; Mehta S; Alhamad T; Bromberg JS; Fischbach B; Aeschbacher T; Ghosh S; Shekhtman G; Dholakia S; Brennan DC; Poggio E; Bloom RD; Jordan SC
    Clin Transplant; 2021 Sep; 35(9):e14402. PubMed ID: 34184326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR.
    Sigdel TK; Archila FA; Constantin T; Prins SA; Liberto J; Damm I; Towfighi P; Navarro S; Kirkizlar E; Demko ZP; Ryan A; Sigurjonsson S; Sarwal RD; Hseish SC; Chan-On C; Zimmermann B; Billings PR; Moshkevich S; Sarwal MM
    J Clin Med; 2018 Dec; 8(1):. PubMed ID: 30583588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation.
    Khush KK; De Vlaminck I; Luikart H; Ross DJ; Nicolls MR
    ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33532456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications.
    Bromberg JS; Brennan DC; Poggio E; Bunnapradist S; Langone A; Sood P; Matas AJ; Mannon RB; Mehta S; Sharfuddin A; Fischbach B; Narayanan M; Jordan SC; Cohen DJ; Zaky ZS; Hiller D; Woodward RN; Grskovic M; Sninsky JJ; Yee JP; Bloom RD
    J Appl Lab Med; 2017 Nov; 2(3):309-321. PubMed ID: 33636851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term mortality after cardiac allograft vasculopathy: implications of percutaneous intervention.
    Agarwal S; Parashar A; Kapadia SR; Tuzcu EM; Modi D; Starling RC; Oliveira GH
    JACC Heart Fail; 2014 Jun; 2(3):281-8. PubMed ID: 24952696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration.
    Lakhani L; Alasfar S; Bhalla A; Aala A; Rosenberg A; Ostrander D; Schollenberger MD; Brennan DC; Lipson EJ
    Transplant Direct; 2021 Feb; 7(2):e656. PubMed ID: 33490381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients.
    Mayer KA; Doberer K; Tillgren A; Viard T; Haindl S; Krivanec S; Reindl-Schwaighofer R; Eder M; Eskandary F; Casas S; Wahrmann M; Regele H; Böhmig GA
    Transpl Int; 2021 Sep; 34(9):1689-1702. PubMed ID: 34448270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low MicroRNA-126 Levels in Right Ventricular Endomyocardial Biopsies Coincide With Cardiac Allograft Vasculopathy in Heart Transplant Patients.
    Heggermont WA; Delrue L; Dierickx K; Dierckx R; Verstreken S; Goethals M; Bartunek J; Vanderheyden M
    Transplant Direct; 2020 May; 6(5):e549. PubMed ID: 32548243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening of cardiac allograft vasculopathy in heart transplant patients with coronary computed tomography angiography.
    Amador AF; Amorim S; Proença T; Vasconcelos M; Tavares Da Silva M; Rebelo J; Carvalho A; Pinheiro-Torres J; Pinho P; Rodrigues R
    Monaldi Arch Chest Dis; 2024 Feb; ():. PubMed ID: 38351838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graft-derived Cell-free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: A Cohort Study on Clinical Validity and Confounding Factors.
    Knüttgen F; Beck J; Dittrich M; Oellerich M; Zittermann A; Schulz U; Fuchs U; Knabbe C; Schütz E; Gummert J; Birschmann I
    Transplantation; 2022 Mar; 106(3):615-622. PubMed ID: 33653997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low clinical utility of routine angiographic surveillance in the detection and management of cardiac allograft vasculopathy in transplant recipients.
    Clague JR; Cox ID; Murday AJ; Charokopos N; Madden BP
    Clin Cardiol; 2001 Jun; 24(6):459-62. PubMed ID: 11403507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High sensitivity troponin I as a biomarker for cardiac allograft vasculopathy: Evaluation of diagnostic potential and clinical utility.
    Patel K; Yadalam A; DeStefano R; Desai S; Almuwaqqat Z; Ko YA; Alras Z; Martini MA; Ejaz K; Alvi Z; Varounis C; Murtagh G; Gupta D; Book W; Quyyumi AA
    Clin Transplant; 2024 Jan; 38(1):e15168. PubMed ID: 37882497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma Donor-derived Cell-free DNA Levels Are Increased During Acute Cellular Rejection After Lung Transplant: Pilot Data.
    Sayah D; Weigt SS; Ramsey A; Ardehali A; Golden J; Ross DJ
    Transplant Direct; 2020 Oct; 6(10):e608. PubMed ID: 33062841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Donor-derived Cell-free DNA to Inform Tapering of Immunosuppression Therapy in Kidney Transplant Recipients: An Observational Study.
    Osuchukwu G; Trevino A; McCormick S; Kaur N; Prigmore B; Al Haj Baddar N; Bloom MS; Demko Z; Gauthier P
    Transplant Direct; 2024 Apr; 10(4):e1610. PubMed ID: 38481964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients.
    Grskovic M; Hiller DJ; Eubank LA; Sninsky JJ; Christopherson C; Collins JP; Thompson K; Song M; Wang YS; Ross D; Nelles MJ; Yee JP; Wilber JC; Crespo-Leiro MG; Scott SL; Woodward RN
    J Mol Diagn; 2016 Nov; 18(6):890-902. PubMed ID: 27727019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome of cardiac allograft vasculopathy: Importance of the International Society for Heart and Lung Transplantation angiographic grading scale.
    Van Keer JM; Van Aelst LNL; Rega F; Droogne W; Voros G; Meyns B; Vanhaecke J; Emonds MP; Janssens S; Naesens M; Van Cleemput J
    J Heart Lung Transplant; 2019 Nov; 38(11):1189-1196. PubMed ID: 31543298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.